Clinical stage Microbiotica is a clinical-stage microbiome company with live biotherapeutic products and biomarkers in IBD, immuno-oncology, and gut epithelial barrier repair, signaling ongoing needs for CROs, contract development, and clinical manufacturing partnerships.

Manufacturing partnerships Recent manufacturing collaboration with Biose Industrie to scale cGMP-compliant clinical batches indicates strong interest in scalable production capabilities; potential sales angle for CDMOs, process development, and supply chain services.

Strategic collaborations Active collaborations with Cancer Research UK, Cambridge University Hospitals, Genentech/Roche, and University of Adelaide suggest opportunities to propose joint development programs, translational research services, and access to broader clinical networks.

Funding momentum Significant Series B funding with investors including Tencent, Cambridge Innovation Capital, Flerie Invest, and IP Group demonstrates strong financial backing and validation, creating openings for strategic partnerships and co-development financing discussions.

Executive leadership New Chief Medical Officer appointment and a clearly defined leadership transition imply focus on clinical strategy, trial execution, and regulatory milestones—opportunities to offer advisory, clinical operations support, or oncology and GI trial consulting.